{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+2%2FMTD&page=2", "query": { "intervention": "Dose level 2/MTD", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+2%2FMTD&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T05:57:12.356Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06567015", "title": "Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "STX-241", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pierre Fabre Medicament", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2024-09-17", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-28T05:57:12.356Z", "location_count": 2, "location_summary": "Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06567015" }, { "nct_id": "NCT03081858", "title": "Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer Cell Transitional", "Non-Muscle Invasive Bladder Cancer", "Bladder Cancer", "Urinary Bladder", "Transitional Cell Carcinoma of the Bladder", "Urinary Bladder Neoplasms", "Urologic Neoplasms", "Urogenital Neoplasms", "Urinary Bladder Diseases", "Urologic Diseases" ], "interventions": [ { "name": "TSD-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lipac Oncology LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 15, "start_date": "2018-05-17", "completion_date": "2021-08-05", "has_results": true, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-09-28T05:57:12.356Z", "location_count": 5, "location_summary": "Tucson, Arizona • Bakersfield, California • Los Angeles, California + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Hanover", "state": "Maryland" }, { "city": "Myrtle Beach", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03081858" }, { "nct_id": "NCT02646748", "title": "Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer (CRC)", "Endometrial Cancer", "Melanoma", "Head and Neck Cancer", "Lung Cancer", "MMR-deficient Tumors", "Breast Cancer", "Pancreatic Cancer", "Renal Cell Carcinoma (RCC)", "Solid Tumors", "UC (Urothelial Cancer)" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "itacitinib", "type": "DRUG" }, { "name": "INCB050465", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2016-01-25", "completion_date": "2020-11-20", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-09-28T05:57:12.356Z", "location_count": 17, "location_summary": "San Francisco, California • Santa Monica, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02646748" }, { "nct_id": "NCT01133990", "title": "FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "FOLFIRI", "type": "DRUG" }, { "name": "E7820", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2010-03-04", "completion_date": "2011-02-18", "has_results": true, "last_update_posted_date": "2023-11-07", "last_synced_at": "2026-09-28T05:57:12.356Z", "location_count": 6, "location_summary": "Denver, Colorado • Berkeley Heights, New Jersey • Mount Holly, New Jersey + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Berkeley Heights", "state": "New Jersey" }, { "city": "Mount Holly", "state": "New Jersey" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01133990" }, { "nct_id": "NCT03454243", "title": "Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "RXDX-106", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2018-02-15", "completion_date": "2018-06-05", "has_results": false, "last_update_posted_date": "2019-04-25", "last_synced_at": "2026-09-28T05:57:12.356Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03454243" }, { "nct_id": "NCT03497689", "title": "EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "Intravenous/Subcutaneous Treprostinil; Oral Treprostinil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "United Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 36, "start_date": "2019-01-31", "completion_date": "2022-05-11", "has_results": true, "last_update_posted_date": "2023-08-07", "last_synced_at": "2026-09-28T05:57:12.356Z", "location_count": 11, "location_summary": "Fresno, California • Torrance, California • Orlando, Florida + 8 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Austell", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03497689" }, { "nct_id": "NCT00426582", "title": "Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Patupilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2006-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-12-09", "last_synced_at": "2026-09-28T05:57:12.356Z", "location_count": 5, "location_summary": "Norwalk, Connecticut • Rockville, Maryland • Detroit, Michigan + 2 more", "locations": [ { "city": "Norwalk", "state": "Connecticut" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00426582" }, { "nct_id": "NCT03894540", "title": "Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "IPN60090", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "IPN60090 single administration", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2019-03-22", "completion_date": "2020-12-21", "has_results": true, "last_update_posted_date": "2022-09-13", "last_synced_at": "2026-09-28T05:57:12.356Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03894540" }, { "nct_id": "NCT03360006", "title": "A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "ABBV-744", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2018-03-16", "completion_date": "2020-12-19", "has_results": false, "last_update_posted_date": "2021-03-24", "last_synced_at": "2026-09-28T05:57:12.356Z", "location_count": 7, "location_summary": "Orange, California • Sacramento, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03360006" }, { "nct_id": "NCT00602693", "title": "T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma", "Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "umbilical cord blood transplantation", "type": "BIOLOGICAL" }, { "name": "Allopurinol", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Total body irradiation", "type": "RADIATION" }, { "name": "Treg infusion", "type": "BIOLOGICAL" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 41, "start_date": "2007-07-23", "completion_date": "2015-04-16", "has_results": false, "last_update_posted_date": "2017-12-02", "last_synced_at": "2026-09-28T05:57:12.356Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00602693" } ] }